MX2013006492A - Nueva forma de administracion de inhibidor de encefalinasa. - Google Patents

Nueva forma de administracion de inhibidor de encefalinasa.

Info

Publication number
MX2013006492A
MX2013006492A MX2013006492A MX2013006492A MX2013006492A MX 2013006492 A MX2013006492 A MX 2013006492A MX 2013006492 A MX2013006492 A MX 2013006492A MX 2013006492 A MX2013006492 A MX 2013006492A MX 2013006492 A MX2013006492 A MX 2013006492A
Authority
MX
Mexico
Prior art keywords
administration
new form
enkephalinase inhibitor
enkephalinase
inhibitor
Prior art date
Application number
MX2013006492A
Other languages
English (en)
Other versions
MX354858B (es
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Xavier Ligneau
Marc Maury
Philippe Robert
Jean-Stephane Julien
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MX2013006492A publication Critical patent/MX2013006492A/es
Publication of MX354858B publication Critical patent/MX354858B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con una nueva formulación de un inhibidor de encefalinasa, tal como racecadotril o dexecadotril, con el proceso para la preparación del mismo y con el uso del mismo en el tratamiento de diarrea.
MX2013006492A 2010-12-10 2011-12-09 Nueva forma de administracion de inhibidor de encefalinasa. MX354858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306397A EP2462922A1 (en) 2010-12-10 2010-12-10 New form of administration of enkephalinase inhibitor
PCT/EP2011/072315 WO2012076691A1 (en) 2010-12-10 2011-12-09 New form of administration of enkephalinase inhibitor

Publications (2)

Publication Number Publication Date
MX2013006492A true MX2013006492A (es) 2013-11-01
MX354858B MX354858B (es) 2018-03-23

Family

ID=45092498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006492A MX354858B (es) 2010-12-10 2011-12-09 Nueva forma de administracion de inhibidor de encefalinasa.

Country Status (31)

Country Link
US (1) US9439853B2 (es)
EP (2) EP2462922A1 (es)
JP (1) JP5847192B2 (es)
KR (1) KR101837685B1 (es)
CN (1) CN103338749B (es)
AP (1) AP3787A (es)
AU (1) AU2011340500B2 (es)
BR (1) BR112013014388A2 (es)
CA (1) CA2820835C (es)
CO (1) CO6731092A2 (es)
CY (1) CY1123056T1 (es)
DK (1) DK2648696T3 (es)
EA (1) EA022730B1 (es)
EC (1) ECSP13012665A (es)
ES (1) ES2791710T3 (es)
HR (1) HRP20200555T1 (es)
HU (1) HUE049273T2 (es)
IL (1) IL226775A (es)
LT (1) LT2648696T (es)
MA (1) MA34724B1 (es)
ME (1) ME03769B (es)
MX (1) MX354858B (es)
NZ (1) NZ611597A (es)
PL (1) PL2648696T3 (es)
PT (1) PT2648696T (es)
RS (1) RS60197B1 (es)
SG (1) SG191068A1 (es)
SI (1) SI2648696T1 (es)
TN (1) TN2013000239A1 (es)
UA (1) UA111835C2 (es)
WO (1) WO2012076691A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
JP6282645B2 (ja) 2012-06-28 2018-02-21 ジヨンソン・アンド・ジヨンソン・コンシユーマー・インコーポレーテツドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． ラセカドトリル脂質組成物
CN104411307B (zh) * 2012-06-28 2017-04-26 麦克内尔-Ppc股份有限公司 消旋卡多曲液体组合物
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物
ES2549127T1 (es) 2014-03-10 2015-10-23 Galenicum Health S.L. Composiciones farmacéuticas que comprenden un principio activo
EP2949318A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
CN105125477A (zh) * 2015-08-19 2015-12-09 黑龙江佰彤儿童药物研究有限公司 一种含消旋卡多曲的药物制剂及制备方法
IT201700099690A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
ATE301999T1 (de) 2000-06-23 2005-09-15 Bioprojet Soc Civ Racecadotril enthaltende trockene pulverformulierung
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1563848A1 (en) * 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
CN101103960B (zh) * 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Also Published As

Publication number Publication date
CO6731092A2 (es) 2013-08-15
IL226775A (en) 2017-09-28
LT2648696T (lt) 2020-05-11
ME03769B (me) 2021-04-20
US20130331423A1 (en) 2013-12-12
BR112013014388A2 (pt) 2016-09-27
CN103338749A (zh) 2013-10-02
SG191068A1 (en) 2013-07-31
CN103338749B (zh) 2017-04-26
EP2462922A1 (en) 2012-06-13
PL2648696T3 (pl) 2020-07-27
CA2820835C (en) 2019-01-08
AP3787A (en) 2016-08-31
EP2648696A1 (en) 2013-10-16
KR20130124335A (ko) 2013-11-13
SI2648696T1 (sl) 2020-07-31
HRP20200555T1 (hr) 2020-07-24
EA022730B1 (ru) 2016-02-29
EP2648696B1 (en) 2020-02-19
JP2014503512A (ja) 2014-02-13
HUE049273T2 (hu) 2020-09-28
MX354858B (es) 2018-03-23
RS60197B1 (sr) 2020-06-30
KR101837685B1 (ko) 2018-03-12
CA2820835A1 (en) 2012-06-14
CY1123056T1 (el) 2021-10-29
ES2791710T3 (es) 2020-11-05
DK2648696T3 (da) 2020-05-04
PT2648696T (pt) 2020-05-13
JP5847192B2 (ja) 2016-01-20
UA111835C2 (uk) 2016-06-24
NZ611597A (en) 2015-01-30
TN2013000239A1 (en) 2014-11-10
AP2013006971A0 (en) 2013-07-31
WO2012076691A1 (en) 2012-06-14
AU2011340500B2 (en) 2016-10-20
MA34724B1 (fr) 2013-12-03
US9439853B2 (en) 2016-09-13
EA201300688A1 (ru) 2014-11-28
ECSP13012665A (es) 2013-08-30
AU2011340500A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MY165754A (en) Catalyst for producing acrylic acids and acrylates
IN2014DN10670A (es)
PH12014501032A1 (en) 2-thiopyrimidinones
NZ702930A (en) Racecadotril liquid compositions
IN2014CN04634A (es)
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012104240A3 (de) Kosmetische verwendung
MX2015008187A (es) Inhibidores de alk deuterados.
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
MX347541B (es) Analogos de acido sialico.
PH12015502706B1 (en) Oral formulation for the treatment of cardiovascular diseases
IN2014DN00123A (es)
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MX2013015419A (es) Dha y epa en la reduccion de estres oxidante.
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
IN2015MN00091A (es)

Legal Events

Date Code Title Description
FG Grant or registration